HEALTH IS WEALTH, IN MORE WAYS THAN ONE - HEALTHCARE OPPORTUNITIES FUND - SBI Mutual Fund
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
HEALTHCARE
OPPORTUNITIES FUND
An open-ended Equity Scheme investing in
healthcare sector
HEALTH IS WEALTH,
IN MORE WAYS THAN ONE.
Presenting SBI healthcare opportunities fund
Under-penetration, rising healthcare spends by households and greater prevalence of chronic diseases drive growth domestically, while
demand for ‘cheaper’ generic drugs in the developed markets and foray into growing emerging markets will drive performance
internationally. SBI Healthcare Opportunities Fund adopts a bottom-up approach to pick pharma companies which have positioned
themselves to capture this potential and have the capability to do so. Invest in this fund and let the saying ‘Health is Wealth’ ring true for
your portfolio.
INVESTMENT To provide the investors with the opportunity of long-term capital appreciation by investing in a
OBJECTIVE diversified portfolio of equity and equity related securities in Healthcare space.
Current Scenario
• The sector has faced a lot of headwinds in the form of heightened scrutiny of plants, channel consolidation leading to price erosion,
price action by regulators in India among others
• We have seen some positive trends in growth in India in the last few quarters along with price erosion in
US showing signs of stabilisation
• With pharma being classified as essential goods, the supply chain and manufacturing should continue for pharma companies
Why invest in SBI Healthcare Opportunities Fund now?
As medicines are an essential commodity, they
would witness limited impact of the slowdown in Unlike the earnings growth seen in the last 3-4
the economy. Hospitals/Diagnostics may see years, there are expectations of reasonable
some short-term impact but medium to growth for the sector in the next 2-3 years
long-term prospects remain positive. Secular Reasonable supported by growth in India, US and API
Demand domestic demand along with normalcy in the US Earnings (Active Pharmaceutical Ingredient) business
Continuity market is expected to support the overall growth Growth
US is the largest pharmaceutical market and
Indian companies command around 40-45%
Current healthcare sector valuations are market share by volume. 40% of business for
reasonable as compared to the valuations seen Indian companies come from the US and
3-4 years back Currency Depreciation should further support
Currency pharma companies’ earnings in the near term
Valuations
API and Intermediates are highly dependent on
China for raw materials. With customers wanting
As countries work towards improving and
to reduce the over reliance on China, India with
expanding their healthcare facilities, spending
low cost labour and good chemistry skills is
on healthcare is expected to increase going
expected to be a natural beneficiary. It might be
ahead leading to further growth opportunities for
Increase in Business difficult to match the prices China offers for
the sector
SHIFT FROM commodity volume products but incentives for
Spending
API investments through API parks/hubs & PLI
CHINA
schemes are steps in the right direction.
Growth in Europe and other regulated markets is
also expected to be good in the current
pandemic situation as some companies are
benefiting from supplies of COVID drugs.
LOw base However, we expect this growth to be structural
in europe in nature. Indian companies are expected to
and other benefit due to low base and reducing market
regulated share of companies from other geographies in
these countries
markets
Source: Internal
FUND DETAILS
• Fund Manager: • Exit Load: For exit within 15 Days from the date of allotment - 0.50%
Mr. Tanmaya Desai For exit after 15 Days from the date of allotment - Nil
• Managing Since: • Entry Load: N.A.
June 2011 • SIP: 'Any Day SIP' Facility is available for Monthly, Quarterly,
• Total Experience: Semi-Annual and Annual frequencies through electronic mode like
Over 12 years OTM / Debit Mandate. Default SIP date will be 10th. In case the SIP due
date is a Non-Business Day, then the immediate following Business
• Quantitative Data: Day will be considered for SIP processing.
Standard Deviation#: 20.64% • Daily: Minimum 500 & in multiples of 1 thereafter for a minimum of
Beta#: 0.87 12 installments (w.e.f. June 04, 2020).
Sharpe Ratio#: 1.06 • Weekly: Minimum `1000 & in multiples of `1 thereafter for a minimum
Portfolio Turnover*: of 6 installments (or) minimum ₹500 & in multiples of ₹1 thereafter for
Equity Turnover: 0.50 minimum one year
Total Turnover: 0.50 • Monthly: Minimum `1000 & in multiples of `1 thereafter for minimum
Total Turnover = Equity + Debt + six months (or) minimum `500 & in multiples of `1 thereafter for
Derivatives
minimum one year
Data as on: 31st May, 2021 • Quarterly: Minimum `1500 & in multiples of `1 thereafter for minimum
one year
#
Source: CRISIL Fund Analyser
• Semi-Annual: Minimum `3000 & in multiples of `1 thereafter for a
*Portfolio Turnover = lower of total sale or total
minimum of 4 installments
purchase for the last 12 months upon Avg. AUM of • Annual: Minimum `5000 & in multiples of `1 thereafter for a
trailing twelve months. Risk Free rate: FBIL Overnight minimum of 4 installments
Mibor rate (3.39% as on 31st May, 2021). • Benchmark Index: S&P BSE HEALTHCARE Index
Calculation: 3 Years Monthly Data Points • Minimum Investment: `5000 & in multiples of `1
Ratios are computed using Total Return Index (TRI) as • Additional Investment: `1000 & in multiples of `1
per SEBI Circular dated Jan 4, 2018. Plans Available: Regular and Direct
Options: Growth and IDCW
IDCW: IDCW stands for ‘Income Distribution cum Capital Withdrawal.’
PORTFOLIO
Stock Name (%) Of Total AUM
Equity Shares
Dr. Reddy's Laboratories Ltd. 10.07
Sun Pharmaceutical Industries Ltd. 9.85
Aurobindo Pharma Ltd. 9.25
Cipla Ltd. 9.00
Lupin Ltd. 8.48
Divi's Laboratories Ltd. 7.95
Alkem Laboratories Ltd. 3.94
Narayana Hrudayalaya Ltd. 3.46
Cadila Healthcare Ltd. 3.26
Max Healthcare Institute Ltd. 3.16
Strides Pharma Science Ltd. 3.02
Gland Pharma Ltd. 2.99
Solara Active Pharma Sciences Ltd. 2.78
JB Chemicals & Pharmaceuticals Ltd. 2.67
Apollo Hospitals Enterprise Ltd. 2.67
Gufic Biosciences Ltd. 2.42
Natco Pharma Ltd. 2.21
Fortis Healthcare Ltd. 2.16
Sequent Scientific Ltd. 2.04
Abbott India Ltd. 2.03
Ajanta Pharma Ltd. 2.02
Glenmark Pharmaceuticals Ltd. 0.94
Total 96.37
Shreno Ltd. 0.35
Total 0.35
Cash, Cash Equivalents And Others 3.28
Grand Total 100.00
Data as on: 31st May, 2021
PERFORMANCE OF SBI Healthcare Opportunities Fund
Fund Managed by Tanmaya Desai
1 Year 3 Years 5 Years Since Inception
Inception Date &
CAGR PTP CAGR PTP CAGR PTP CAGR PTP Managing Since
Returns ( % ) Returns ( ` ) Returns ( % ) Returns ( ` ) Returns ( % ) Returns ( ` ) Returns ( % ) Returns ( ` )
SBI Healthcare
57.26 15726 26.06 20043 10.53 16504 16.60 289547 Inception Date
Opportunities Fund
05-07-1999
Scheme Benchmark: -
54.27 15725 24.45 19286 10.68 16610 14.94 211693
S&P BSE Health Care TRI
Managing Since
Additional Benchmark: - Jun-2011
S&P BSE Sensex TRI 61.66 16166 15.04 15230 15.68 20721 13.79 169759
Notes:
a. The details of the period since the Fund Manager is managing the scheme & inception date provided alongside of the table.
Mr. Tanmay Desai only manages SBI Healthcare Opportunities Fund
b. Different plans shall have a different expense structure. The performance provided for SBI Healthcare Opportunities Fund are of
regular plan - IDCW Option and is Net of IDCW distribution tax, if any. SBI Healthcare Opportunities Fund Growth option was
introduced on 31/12/04. In case of return calculated the IDCW option, it is assumed that IDCW declared under the schemes have
been reinvested at the prevailing NAV
c. Past performance may or may not be sustained in the future and the same may not necessarily provide the basis for comparison with
other investment
d. Load is not considered for computation of returns
e. Period for which the scheme’s performance has been provided is computed basis last working day of the month-end preceding the
date of advertisement i.e. 31st May, 2021. In case, the start/end date of the concerned period is a non-business day, the NAV
of the previous date is considered for computation of returns
f. SBI Healthcare Opportunities Fund: As TRI data is not available since inception of SBI Healthcare Opportunities Fund, additional
benchmark performance is calculated using composite CAGR of S&P BSE Health Care PRI values from 05-Jul-99 to 30-Dec-07 and
TRI values since 31-Dec-07
g. The performance of the schemes is benchmarked to the Total Return variant of the Index
IDCW: IDCW stands for ‘Income Distribution cum Capital Withdrawal.’
SBI Healthcare Opportunities Fund is suitable for investors who are seeking^: Scan the QR code Distributed by
Moder
e a
derat Hightely
Mo
to te Hi
a g
er
od w
● Long-term capital appreciation
M Lo
h
Ver
y Hig
● Equity investments in stocks of companies in the healthcare sector
Low
h
RISKOMETER
Investors understand that their principal
will be at very high risk ^Investors should consult their financial advisers if in doubt about whether the product is suitable for them.
Toll-free: 1800 209 3333 SMS: ‘SBIMF ’ to 7065611100 Visit: www.sbimf.com Follow us:
Mutual Fund investments are subject to market risks,
read all scheme related documents carefully.
You can also read
